We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Soliris

News List

EU Commission Grants New Indication for Soliris for Refractory gMG pharmaceutical-technology
August 23, 2017
Alexion Pharmaceuticals announced the European Commission (EC) approved the extension of the indication for Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR
Alexion moves to bolster patent protection of Soliris pharmafile
August 18, 2017
It’s no wonder that the company is stacking its patent defences against any potential biosimilar encroachment onto its sales territory in the short term future.
Alexion wins 3 new Soliris patents as Amgen works on biosimilar of pricey drug fiercepharma
August 17, 2017
Rare-disease drug Soliris is one of the most expensive drugs in the world, making it a prime target for biosimilars.

Previous page 1 2 Next page